Henry James International Management Inc. Decreases Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)

Henry James International Management Inc. reduced its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 16.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,851 shares of the biotechnology company's stock after selling 3,500 shares during the quarter. Henry James International Management Inc.'s holdings in Ascendis Pharma A/S were worth $2,458,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Legato Capital Management LLC lifted its stake in shares of Ascendis Pharma A/S by 7.5% during the 4th quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company's stock worth $264,000 after purchasing an additional 134 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth $30,000. GAMMA Investing LLC raised its stake in Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after buying an additional 214 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in Ascendis Pharma A/S by 0.3% in the third quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company's stock valued at $11,717,000 after buying an additional 228 shares during the last quarter. Finally, Avior Wealth Management LLC raised its stake in Ascendis Pharma A/S by 3.0% in the third quarter. Avior Wealth Management LLC now owns 8,212 shares of the biotechnology company's stock valued at $1,226,000 after buying an additional 240 shares during the last quarter.

Remove Ads

Ascendis Pharma A/S Stock Performance

Ascendis Pharma A/S stock traded up $5.05 during midday trading on Wednesday, hitting $155.86. 861,353 shares of the company were exchanged, compared to its average volume of 450,752. The firm has a market capitalization of $9.46 billion, a PE ratio of -21.95 and a beta of 0.64. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $158.00. The business has a fifty day simple moving average of $136.59 and a two-hundred day simple moving average of $134.09.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.64. As a group, equities analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have commented on ASND. Oppenheimer decreased their price target on Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating for the company in a research note on Friday, November 15th. JPMorgan Chase & Co. increased their price target on Ascendis Pharma A/S from $167.00 to $168.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Cantor Fitzgerald increased their price target on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research note on Tuesday, February 25th. Evercore ISI increased their price target on Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research note on Tuesday, February 18th. Finally, StockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research note on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $202.36.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.